Cargando…
MicroRNA-566 activates EGFR signaling and its inhibition sensitizes glioblastoma cells to nimotuzumab
BACKGROUND: Epidermal growth factor receptor (EGFR) is amplified in 40% of human glioblastomas. However, most glioblastoma patients respond poorly to anti-EGFR therapy. MicroRNAs can function as either oncogenes or tumor suppressor genes, and have been shown to play an important role in cancer cell...
Autores principales: | Zhang, Kai-Liang, Zhou, Xuan, Han, Lei, Chen, Lu-Yue, Chen, Ling-Chao, Shi, Zhen-Dong, Yang, Ming, Ren, Yu, Yang, Jing-Xuan, Frank, Thomas S, Zhang, Chuan-Bao, Zhang, Jun-Xia, Pu, Pei-Yu, Zhang, Jian-Ning, Jiang, Tao, Wagner, Eric J, Li, Min, Kang, Chun-Sheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3999939/ https://www.ncbi.nlm.nih.gov/pubmed/24650032 http://dx.doi.org/10.1186/1476-4598-13-63 |
Ejemplares similares
-
Radiotherapy Plus Temozolomide With or Without Nimotuzumab Against the Newly Diagnosed EGFR-Positive Glioblastoma: A Retrospective Cohort Study
por: She, Lei, et al.
Publicado: (2022) -
Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma
por: Ronellenfitsch, Michael W., et al.
Publicado: (2018) -
Nimotuzumab, an Anti-EGFR Monoclonal Antibody, in the Treatment of Nasopharyngeal Carcinoma
por: Liang, Renba, et al.
Publicado: (2021) -
An EGCG Derivative in Combination with Nimotuzumab for the Treatment of Wild-Type EGFR NSCLC
por: Huang, Yanping, et al.
Publicado: (2023) -
Clinical features, diagnosis, and treatment of Peutz-Jeghers syndrome: Experience with 566 Chinese cases
por: Xu, Zu-Xin, et al.
Publicado: (2023)